MeiraGTx Holdings plc
NASDAQ:MGTX 3:59:41 PM EDT
| Market Cap (Intraday) | 669.96M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $14.84 |
| 50-Day MA | $14.00 |
| 200-Day MA | $14.41 |
MeiraGTx Holdings plc Stock, NASDAQ:MGTX
430 East 29th Street, 14th floor, New York, New York 10016
Cayman Islands
Phone: +1.646.860.7985
Number of Employees: 219
Description
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.